Logo image of ATHE

ALTERITY THERAPEUTICS-ADR (ATHE) Stock Fundamental Analysis

NASDAQ:ATHE - Nasdaq - US02155X2053 - ADR - Currency: USD

3.9  -0.19 (-4.61%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ATHE. ATHE was compared to 555 industry peers in the Biotechnology industry. Both the profitability and financial health of ATHE have multiple concerns. ATHE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ATHE has reported negative net income.
In the past year ATHE has reported a negative cash flow from operations.
In the past 5 years ATHE always reported negative net income.
In the past 5 years ATHE always reported negative operating cash flow.
ATHE Yearly Net Income VS EBIT VS OCF VS FCFATHE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -99.48%, ATHE is doing worse than 76.22% of the companies in the same industry.
ATHE has a Return On Equity of -138.60%. This is in the lower half of the industry: ATHE underperforms 61.26% of its industry peers.
Industry RankSector Rank
ROA -99.48%
ROE -138.6%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATHE Yearly ROA, ROE, ROICATHE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATHE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATHE Yearly Profit, Operating, Gross MarginsATHE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200K -400K -600K

More info and screens

3

2. Health

2.1 Basic Checks

ATHE does not have a ROIC to compare to the WACC, probably because it is not profitable.
ATHE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ATHE Yearly Shares OutstandingATHE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M
ATHE Yearly Total Debt VS Total AssetsATHE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -7.45, we must say that ATHE is in the distress zone and has some risk of bankruptcy.
ATHE has a worse Altman-Z score (-7.45) than 68.83% of its industry peers.
ATHE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ATHE (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.45
ROIC/WACCN/A
WACC8.99%
ATHE Yearly LT Debt VS Equity VS FCFATHE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

A Current Ratio of 3.54 indicates that ATHE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.54, ATHE is in line with its industry, outperforming 40.90% of the companies in the same industry.
ATHE has a Quick Ratio of 3.54. This indicates that ATHE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.54, ATHE is in line with its industry, outperforming 42.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.54
Quick Ratio 3.54
ATHE Yearly Current Assets VS Current LiabilitesATHE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 20.00% over the past year.
ATHE shows a strong growth in Revenue. In the last year, the Revenue has grown by 111.58%.
ATHE shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.86% yearly.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
Revenue 1Y (TTM)111.58%
Revenue growth 3Y134.93%
Revenue growth 5Y19.86%
Sales Q2Q%-6%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATHE Yearly Revenue VS EstimatesATHE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATHE. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATHE Price Earnings VS Forward Price EarningsATHE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATHE Per share dataATHE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATHE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALTERITY THERAPEUTICS-ADR

NASDAQ:ATHE (7/1/2025, 2:27:44 PM)

3.9

-0.19 (-4.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-28 2025-02-28
Earnings (Next)N/A N/A
Inst Owners13.83%
Inst Owner Change94.65%
Ins Owners2.85%
Ins Owner ChangeN/A
Market Cap57.73M
Analysts100
Price TargetN/A
Short Float %0.84%
Short Ratio2.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 329.41
P/FCF N/A
P/OCF N/A
P/B 6.41
P/tB 6.41
EV/EBITDA N/A
EPS(TTM)-0.9
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS0.01
BVpS0.61
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.48%
ROE -138.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 2.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.54
Quick Ratio 3.54
Altman-Z -7.45
F-ScoreN/A
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)1203.55%
Cap/Sales(5y)751.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)111.58%
Revenue growth 3Y134.93%
Revenue growth 5Y19.86%
Sales Q2Q%-6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.08%
OCF growth 3YN/A
OCF growth 5YN/A